ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag tuberculosis fda business regulation

Updated Mar 8
A healthcare worker holds up three syringes with clear medicine
To Booster or Not: Scientists and Regulators Debate
Jef Akst | Sep 16, 2021 | 7 min read
President Biden’s planned rollout of additional COVID-19 vaccine doses is set to begin next week, but questions remain about who should get them.
FDA Gives Nod to Melanoma Drug
Jef Akst | Sep 8, 2014 | 2 min read
The US Food and Drug Administration last week approved the first of a new type of immunotherapy that aims to pit a patient’s own immune system against her cancer.
Regulations And Poor Communication Slow Pediatric Vaccine Development
Kathryn Brown | May 26, 1996 | 8 min read
Vaccine Development Well-intentioned immunization efforts ignore economic realities, observers contend. By all accounts, the 1990s should be a monumental decade for pediatric vaccines. Wielding new molecular tools like genetic engineering, scientists can craft safer and more creative vaccines than ever imagined. Yet poor communication and disparate desires among industry players plague the vaccine pipeline, according to insiders. As a result, they say, vaccine R&D is taking a hit, investors
In Vitro Diagnostics Firms Frustrated By FDA Delays
Robert Finn | Mar 2, 1997 | 6 min read
Sidebar: In Vitro Diagnostics (IVD) industry -- more information Manufacturers of devices that test fluids or tissues outside the body say the agency's excessively high standard hinders innovation. Photo: Feit's Photography MAJOR BLOW: National Medical Device Coalition’s Wayne Barlow says delays in FDA approval devastate small companies. The in vitro diagnostics (IVD) industry has long been frustrated by lengthy delays in the United States Food and Drug Administration (FDA) product-appr
Banking on iPSCs
Kerry Grens | Sep 1, 2014 | 5 min read
A flurry of induced pluripotent stem cell banks are coming online, but they face significant business challenges.
Banking on iPSCs
Kerry Grens | Jun 29, 2014 | 6 min read
A flurry of induced pluripotent stem cell banks are coming online, but they face significant business challenges.
Texas Stem Cell Law Opens Door for Controversial Treatments
Anna Azvolinsky | Mar 27, 2018 | 7 min read
The Scientist looks at one such Houston-based purveyor that has been treating patients abroad for years with mesenchymal stem cells.
Updated July 9
Track COVID-19 Vaccines Advancing Through Clinical Trials
The Scientist | Apr 7, 2020 | 10+ min read
Find the latest updates in this one-stop resource, including efficacy data and side effects of approved shots, as well as progress on new candidates entering human studies.
The Proteasome: A Powerful Target for Manipulating Protein Levels
John Hines and Craig M. Crews | May 1, 2017 | 10+ min read
The proteasome’s ability to target and degrade specific proteins is proving useful to researchers studying protein function or developing treatments for diseases.
2019 Top 10 Innovations
The Scientist | Dec 1, 2019 | 10+ min read
From a mass photometer to improved breath biopsy probes, these new products are poised for scientific success.

Run a Search

ADVERTISEMENT